Panacea Life Sciences Holdings, Inc. Debt Securities, Available-for-sale, Realized Gain
Panacea Life Sciences Holdings, Inc. (PLSH) reported Debt Securities, Available-for-sale, Realized Gain of $22.82 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-01.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGain · last filed 2024-04-01
- Panacea Life Sciences Holdings, Inc. debt securities, available-for-sale, realized gain for the quarter ending 2022-12-31 was $0.00.
- Panacea Life Sciences Holdings, Inc. debt securities, available-for-sale, realized gain for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Panacea Life Sciences Holdings, Inc. debt securities, available-for-sale, realized gain for the quarter ending 2022-06-30 was $22.82K.
- Panacea Life Sciences Holdings, Inc. debt securities, available-for-sale, realized gain for the quarter ending 2021-12-31 was $0.00.
- Panacea Life Sciences Holdings, Inc. debt securities, available-for-sale, realized gain for fiscal 2022 was $22.82K, a 85.77% decline from fiscal 2021.
- Panacea Life Sciences Holdings, Inc. debt securities, available-for-sale, realized gain for fiscal 2021 was $160.30K.
| Period end | Debt Securities, Available-for-sale, Realized Gain 3 month | Debt Securities, Available-for-sale, Realized Gain 6 month | Debt Securities, Available-for-sale, Realized Gain 9 month | Debt Securities, Available-for-sale, Realized Gain 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $22.82K derived: sum of 3 quarters · filed 2024-04-01 | $22.82K 10-K · filed 2024-04-01 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $22.82K derived: sum of 2 quarters · filed 2023-11-14 | $22.82K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $22.82K 10-Q · filed 2023-08-15 | $22.82K 10-Q · filed 2023-08-15 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $160.30K derived: sum of 2 quarters · filed 2023-03-30 | $160.30K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $160.30K 10-Q · filed 2022-11-14 | $160.30K 10-Q · filed 2022-11-14 |